Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
123.2 EUR | -0.73% | +0.08% | +3.10% |
23/04 | Reply S.P.A. Approves the Dividend, Payable on 22 May 2024 | CI |
22/04 | Laife Reply Develosd, in Collaboration with IEO (European Institute of Oncology), the Value Based Medicine, a Web Platform | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: IT Services & Consulting
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.10% | 4.94B | B+ | ||
-7.42% | 31.57B | B+ | ||
+0.21% | 15.14B | C- | ||
-6.71% | 8.91B | B | ||
+6.83% | 7.48B | C | ||
-45.75% | 4.44B | - | - | |
+12.35% | 2.99B | D | ||
+8.53% | 2.44B | - | ||
-13.45% | 2.36B | - | C | |
-15.17% | 2.06B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- REY Stock
- Ratings Reply S.p.A.